Stocklytics Platform
Asset logo for symbol TNXP
Tonix Pharmaceuticals Holding
TNXP49
$0.13arrow_drop_up0.68%$0.00
High Value
Penny Stock
Asset logo for symbol TNXP
TNXP49

$0.13

arrow_drop_up0.68%

Performance History

Chart placeholder
Key Stats
Open$0.14
Prev. Close$0.14
EPS-139.08
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$18.35M
PE Ratio-
LOWHIGH
Day Range0.12
0.14
52 Week Range0.12
5.50
Ratios
EPS-139.08

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About Tonix Pharmaceuticals Holding (TNXP)

Tonix Pharmaceuticals Holding Corp (TNXP) is a pharmaceutical company that focuses on the research and development of treatments for central nervous system (CNS) disorders. The company is dedicated to improving the lives of patients suffering from conditions such as fibromyalgia, post-traumatic stress disorder (PTSD), and agitation in Alzheimer's disease.
Founded in 2007, Tonix Pharmaceuticals has made significant progress in developing innovative therapeutics for CNS disorders. The company's lead product candidate, TNX-102 SL, is a potential treatment for fibromyalgia and PTSD. TNX-102 SL is designed to be taken sublingually, allowing for rapid and sustained drug delivery. Clinical trials have shown promising results, demonstrating the potential of TNX-102 SL to reduce pain and improve sleep quality in fibromyalgia patients.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Seth Lederman M.D.
Headquarters
Chatham
Employees
117
Exchange
NASDAQ
add Tonix Pharmaceuticals Holding to watchlist

Keep an eye on Tonix Pharmaceuticals Holding

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the 52-week high and low for Tonix Pharmaceuticals Holding (TNXP)?

For Tonix Pharmaceuticals Holding (TNXP), the 52-week high is $5.5, which is 4.07K% from the current price. The 52-week low is $0.12, the current price is 10% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

What is Tonix Pharmaceuticals Holding's (TNXP) price per share?

The current price per share for Tonix Pharmaceuticals Holding (TNXP) is $0.13. The stock has seen a price change of $0 recently, indicating a 0.69% change. This reflects the stock's recent market performance and investor sentiment.
help

Is Tonix Pharmaceuticals Holding (TNXP) a growth stock?

Tonix Pharmaceuticals Holding (TNXP) has shown an average price growth of -6.65% over the past three years. It has received a score of -7 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Tonix Pharmaceuticals Holding as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Tonix Pharmaceuticals Holding (TNXP) stock price performance year to date (YTD)?

As of the latest data, Tonix Pharmaceuticals Holding (TNXP) has a year-to-date price change of -99.01%. Over the past month, the stock has experienced a price change of -26.42%. Over the last three months, the change has been -70.34%. Over the past six months, the figure is -97.91%. Looking at a longer horizon, the five-year price change stands at -100%.
help

Is Tonix Pharmaceuticals Holding (TNXP) a profitable company?

Tonix Pharmaceuticals Holding (TNXP) has a net income of -$116.66M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 38.97% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -831.48% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $7.77M, although specific revenue growth data is currently not available. The gross profit is $3.03M. Operating income is noted at -$118.38M. Furthermore, the EBITDA is -$90.77M.
help

What is the market capitalization of Tonix Pharmaceuticals Holding (TNXP)?

Tonix Pharmaceuticals Holding (TNXP) has a market capitalization of $18.35M. The average daily trading volume is 0.13, indicating the stock's liquidity and investor engagement.

News

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024
MPOX
VACCINE
TONIX PHARMACEUTICALS
TNX-801
Nov 1, 2024

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024

Tonix Pharmaceuticals to Present at BIO-Europe® 2024
TONIX PHARMACEUTICALS
BIO-EUROPE
PAIN MANAGEMENT
PUBLIC HEALTH
CENTRAL NERVOUS SYSTEM
IMMUNOLOGY
Oct 29, 2024

Tonix Pharmaceuticals to Present at BIO-Europe® 2024

Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat Migraines
MIGRAINE
PATENT
ZEMBRACE SYMTOUCH
SUBCUTANEOUS DELIVERY
Sep 27, 2024

Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat Migraines

Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines
TONIX PHARMACEUTICALS
TOSYMRA
MIGRAINE
PATENT
Sep 19, 2024

Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines

Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO’s Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency
TONIX PHARMACEUTICALS
MPOX VACCINE
WHO
PUBLIC HEALTH EMERGENCY
Sep 16, 2024

Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO’s Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency

Tonix Pharmaceuticals Launches National Awareness Campaign on the Impact of Gastroparesis or Stomach Paralysis on the Absorption of Oral Migraine Medications at PAINWeek
GASTROPARESIS
MIGRAINE
NON-ORAL MEDICATIONS
AWARENESS CAMPAIGN
Sep 6, 2024

Tonix Pharmaceuticals Launches National Awareness Campaign on the Impact of Gastroparesis or Stomach Paralysis on the Absorption of Oral Migraine Medications at PAINWeek

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level